Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | PTAFR | P25105 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86416 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MAPTGAACRHBPCRHR2 | |
| SCHEMBL81215 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MAPTGAACRHBPCRHR2 | |
| SCHEMBL29475072 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MAPTGAACRHBPCRHR2 | |
| SCHEMBL86772 | 0.82 | GAA (0.39) | ALDH1A1MAPTGAACRHBPCRHR2 | |
| SCHEMBL86502 | 0.80 | PTAFR (0.43) | ALDH1A1MAPTGAAHDAC8PTAFR | |
| SCHEMBL15119791 | 0.78 | SLC6A2 (0.39) | ALDH1A1MAPTHDAC8PTAFRMEN1 | |
| SCHEMBL86404 | 0.77 | HDAC8 (0.35) | ALDH1A1MAPTGAAHDAC8PTAFR | |
| SCHEMBL86811 | 0.77 | PTAFR (0.38) | ALDH1A1MAPTGAAHDAC8PTAFR | |
| SCHEMBL86504 | 0.75 | MAPK10 (0.37) | ALDH1A1MAPTHDAC8PTAFRMEN1 | |
| SCHEMBL29475063 | 0.75 | POLB (0.38) | ALDH1A1MAPTPTAFRKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | claimed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | claimed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | claimed |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | BAYER CONSUMER CARE AG (CH) | 2021-11-30 | — | — | US | disclosed |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2021-06-24 | — | — | US | disclosed |
| US-10925880-B2 | Combination of PI3K-inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| WO-2020164997-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-20 | — | — | WO | disclosed |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | BAYER CONSUMER CARE AG (CH) | 2020-07-16 | — | — | US | disclosed |
| EP-3645005-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | Bayer Consumer Care AG (CH) | 2020-05-06 | — | — | EP | disclosed |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-22 | — | — | US | disclosed |
| US-10383877-B2 | Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | disclosed |
| EP-2168582-A1 | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168583-A1 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 4419/4885MAPT 844/4885GAA 522/4885 |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | AR, PIK3CA, AKT3 | ALDH1A1 3255/4885MAPT 557/4885GAA 3322/4885 |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | ALDH1A1 4300/4885MAPT 2333/4885GAA 1455/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | ALDH1A1 4097/4885MAPT 1939/4885GAA 1252/4885 |
| US-10383877-B2 | Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | MCL1, BCL9, BCL3 | ALDH1A1 1389/4885MAPT 4623/4885GAA 2276/4885 |
| US-10925880-B2 | Combination of PI3K-inhibitors | BCL9L, BCL9, MALT1 | ALDH1A1 4001/4885MAPT 4487/4885GAA 3097/4885 |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BCL9L, BCL9, MALT1 | ALDH1A1 4001/4885MAPT 4487/4885GAA 3097/4885 |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | AR, GSK3B, PIK3CA | ALDH1A1 3560/4885MAPT 799/4885GAA 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.